Stocks and InvestingStocks and Investing
Mon, March 21, 2022
Sun, March 20, 2022
Fri, March 18, 2022
Thu, March 17, 2022
Wed, March 16, 2022
Tue, March 15, 2022

David Lebowitz Maintained (ASND) at Buy with Increased Target to $197 on, Mar 15th, 2022


Published on 2024-10-27 20:05:29 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $180 to $197 on, Mar 15th, 2022.

David has made no other calls on ASND in the last 4 months.



There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022


These are the ratings of the 4 analyists that currently disagree with David


  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $194 on, Monday, March 14th, 2022
  • Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $170 on, Thursday, March 3rd, 2022
  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $117 on, Thursday, March 3rd, 2022
  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022